Literature DB >> 11078433

Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells.

B R Brehm1, D Bertsch, J von Fallois, S C Wolf.   

Abstract

Endothelin-1 (ET-1) plays an important role in atherogenesis. The aim of the study reported here was to investigate the effects of the third generation beta-blockers nebivolol and carvedilol on ET-1 liberation, preproendothelin-1 production and on proliferation of human coronary cells. Human coronary endothelial (HEC) and smooth muscle cells (HCSMC) were grown with carvedilol or nebivolol (10(-7)-10(-5) mol/l). Incubation for 1, 2 or 7 days resulted in an 80% concentration- and time-dependent reduction in HCSMC proliferation. beta-blockers such as propranolol or metoprolol did not influence cell proliferation. Nebivolol (10(-7) mol/l) inhibited accelerated HCSMC proliferation in the presence of growth factors such as transforming growth factor-beta1 or platelet-derived growth factor BB. During incubation with nebivolol or carvedilol ET-1 secretion decreased. For nebivolol this is a result of a reduction in preproendothelin-1 mRNA levels. beta-blockers of the third generation that reduce the cell proliferation and ET-1 secretion may represent strategies with great promise for antiproliferative therapy of coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11078433     DOI: 10.1097/00005344-200036051-00117

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  14 in total

1.  Nebivolol improves coronary flow reserve in patients with idiopathic dilated cardiomyopathy.

Authors:  Dogan Erdogan; Hakan Gullu; Mustafa Caliskan; Ozgur Ciftci; Semra Baycan; Aylin Yildirir; Haldun Muderrisoglu
Journal:  Heart       Date:  2006-10-25       Impact factor: 5.994

2.  A Novel function of Nebivolol: Stimulation of Adipose-derived Stem Cell Proliferation and Inhibition of Differentiation.

Authors:  Dong Lin; Joana E Ochoa; Zahra Barabadi; Andreas B Pfnur; Stephen E Braun; Reza Izadpanah; Eckhard Alt
Journal:  J Stem Cells Regen Med       Date:  2020-05-27

3.  Use of fat-fed rats to study the metabolic and vascular sequelae of obesity and beta-adrenergic antagonism.

Authors:  Melinda Frye; Ivan McMurtry; E Christopher Orton; Karen Fagan
Journal:  Comp Med       Date:  2009-06       Impact factor: 0.982

4.  Association of cystatin C with ischemia in patients with coronary heart disease.

Authors:  Rajet Deo; Michael G Shlipak; Joachim H Ix; Sadia Ali; Nelson B Schiller; Mary A Whooley
Journal:  Clin Cardiol       Date:  2009-11       Impact factor: 2.882

5.  The association of endothelin-1 with markers of oxidative stress in a biethnic South African cohort: the SABPA study.

Authors:  Christine Susara du Plooy; Catharina Martha Cornelia Mels; Hugo Willem Huisman; Ruan Kruger
Journal:  Hypertens Res       Date:  2016-09-29       Impact factor: 3.872

Review 6.  Beta-blockers and coronary flow reserve: the importance of a vasodilatory action.

Authors:  Maurizio Galderisi; Arcangelo D'Errico
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Chronic Nebivolol Treatment Suppresses Endothelin-1-Mediated Vasoconstrictor Tone in Adults With Elevated Blood Pressure.

Authors:  Kyle J Diehl; Brian L Stauffer; Caitlin A Dow; Tyler D Bammert; Danielle L Brunjes; Jared J Greiner; Christopher A DeSouza
Journal:  Hypertension       Date:  2016-04-25       Impact factor: 10.190

Review 8.  [Third generation beta-blockers: current state of research on vasodilating beta-blockers].

Authors:  Dennis Ladage; Christian Reidenbach; Albert Lichtenthal; Robert Schwinger; Klara Brixius
Journal:  Wien Med Wochenschr       Date:  2009

9.  A comparative study of nebivolol and (S) atenolol on blood pressure and heart rate on essential hypertensive patients.

Authors:  G N Sahana; N Sarala; T N Kumar; V Lakshmaiah
Journal:  Indian J Pharmacol       Date:  2010-12       Impact factor: 1.200

10.  Propranolol treatment of infantile hemangioma endothelial cells: A molecular analysis.

Authors:  Jessica Stiles; Clarissa Amaya; Robert Pham; Rebecca K Rowntree; Mary Lacaze; Arlynn Mulne; Joyce Bischoff; Victor Kokta; Laura E Boucheron; Dianne C Mitchell; Brad A Bryan
Journal:  Exp Ther Med       Date:  2012-08-03       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.